# Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

> **NCT01521559** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 183 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion

## Interventions

- **PROCEDURE:** Macular Laser Photocoagulation
- **DRUG:** Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

## Key facts

- **NCT ID:** NCT01521559
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-08
- **Final completion:** 2014-03
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2014-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01521559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01521559, "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01521559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*